PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
National Institutes of Health Clinical Center (CC) ( National Institute of Mental Health (NIMH) )
ClinicalTrials.gov Identifier:
NCT00250172
First received: November 5, 2005
Last updated: September 16, 2014
Last verified: September 2014
  Purpose

The purpose of this study is to measure a particular protein in the brain called the phosphodiesterase by using the imaging techniques of positron emission tomography (PET) and magnetic resonance imaging (MRI).


Condition Intervention Phase
Dosimetry
Healthy
Drug: [C-11](R)-rolipram
Phase 1

Study Type: Interventional
Study Design: Primary Purpose: Treatment
Official Title: PET Whole Body Biodistribution and Test Retest Brain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram

Further study details as provided by National Institutes of Health Clinical Center (CC):

Enrollment: 26
Study Start Date: October 2005
Study Completion Date: February 2009
Primary Completion Date: February 2009 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: [C-11](R)-rolipram
    N/A
Detailed Description:

Both basic and clinical studies have indicated that the 3', 5'-cyclic adenosine monophosphate (cAMP) system plays critical roles in several brain diseases, particularly in mood disorders and drug addiction. cAMP is synthesized from adenosine 5'-triphosphate (ATP) by adenylyl cyclase and metabolized by cyclic nucleotide phosphodiesterases (PDEs). Among components of the cAMP pathway, PDE4 appears to be critical for antidepressant effects. 4-[3-(cyclopentoxyl)-4-methoxyphenyl]-2-pyrrolidone (rolipram) is an inhibitor of PDE4. As a positron emission tomography (PET) brain imaging agent, rolipram has good properties such as high affinity of 1-2 nM and appropriate lipophilicity (Log P) of ~3. A rat study gave an estimation of low radiation absorbed doses of the active enantiomer (R)-[11C]rolipram. ciociWEge quality. Therefore, R-[11C]rolipram is a promising PET ligand. However, radiation absorbed doses have not been estimated from human whole body imaging studies and a method to measure binding of (R)-[11C]rolipram in human brain has not been established.

< TAB>

The purposes of this protocol are to estimate radiation absorbed doses of (R)-[11C]rolipram by performing whole body imaging studies on healthy human subjects and also to establish an accurate method to measure PDE4 levels in brain by performing test retest brain imaging studies. The results of this overall study are required to apply this PET ligand in various neurological and psychiatric disorders in the future.

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria
  • INCLUSION CRITERIA:

All subjects must be healthy and aged 18 65 years.

EXCLUSION CRITERIA:

PART 1 (WHOLE BODY IMAGING STUDIES):

  1. Current psychiatric disease, substance abuse or severe systemic disease based on history and physical exam, poor vision or hearing.
  2. Laboratory tests with clinically significant abnormalities.
  3. Prior participation in other research protocols or clinical care in the last year such that radiation exposure including that from this protocol would exceed a half of the annual limits. Because human dosimetry of (R)-[(11)C]rolipram has been estimated using rhesus monkeys, the total exposure including that from the (R)-[(11)C]rolipram whole body imaging study will be limited to a half of the RSC guidelines.
  4. Pregnancy and breast feeding.
  5. Positive HIV test.
  6. Positive urine drug screen.

PART 2 (TEST RETEST BRAIN IMAGING STUDIES):

  1. Current psychiatric disease, substance abuse or severe systemic disease based on history and physical exam, poor vision or hearing.
  2. Laboratory tests with clinically significant abnormalities.
  3. Prior participation in other research protocols or clinical care in the last year such that radiation exposure would exceed the annual limits. Results of part 1 will be used to calculate total radiation exposure within a year.
  4. Pregnancy and breast feeding.
  5. Claustrophobia.
  6. Presence of ferromagnetic metal in the body or heart pacemaker.
  7. Positive HIV test.
  8. A history of brain disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00250172

Locations
United States, Maryland
National Institutes of Health Clinical Center, 9000 Rockville Pike
Bethesda, Maryland, United States, 20892
Sponsors and Collaborators
Investigators
Principal Investigator: Masahiro Fujita, M.D. National Institute of Mental Health (NIMH)
  More Information

Publications:
Responsible Party: National Institutes of Health Clinical Center (CC) ( National Institute of Mental Health (NIMH) )
ClinicalTrials.gov Identifier: NCT00250172     History of Changes
Other Study ID Numbers: 060002, 06-M-0002
Study First Received: November 5, 2005
Last Updated: September 16, 2014
Health Authority: United States: Federal Government

Keywords provided by National Institutes of Health Clinical Center (CC):
Dosimetry
Pharmacokinetics
Compartment Analysis
Reproducibility
Healthy Volunteer
HV

Additional relevant MeSH terms:
Rolipram
Phosphodiesterase 4 Inhibitors
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Pharmacologic Actions
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 22, 2014